[
  {
    "ts": null,
    "headline": "Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat",
    "summary": "Discover why Bristol-Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.",
    "url": "https://finnhub.io/api/news?id=907787857db5ccbe5c072c7d7663430876eb3c8817bce9bb862a5e4ce876a34a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754067600,
      "headline": "Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat",
      "id": 136178514,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why Bristol-Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.",
      "url": "https://finnhub.io/api/news?id=907787857db5ccbe5c072c7d7663430876eb3c8817bce9bb862a5e4ce876a34a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields",
    "summary": "Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn more about BMY stock here.",
    "url": "https://finnhub.io/api/news?id=0868367082a180645bdb6e175cd001d9cb04a5e17ef63309643b6f4b5b7d3645",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754055773,
      "headline": "Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields",
      "id": 136168806,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352338867/image_1352338867.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn more about BMY stock here.",
      "url": "https://finnhub.io/api/news?id=0868367082a180645bdb6e175cd001d9cb04a5e17ef63309643b6f4b5b7d3645"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline",
    "summary": "Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline",
    "url": "https://finnhub.io/api/news?id=79abc80ff93d4138ec08bf76d30e0cf991efa8dba6556a16ccbb396e2d89a90d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754054729,
      "headline": "Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline",
      "id": 136167523,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=79abc80ff93d4138ec08bf76d30e0cf991efa8dba6556a16ccbb396e2d89a90d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)",
    "summary": "Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after earnings. Read the latest stock analysis here.",
    "url": "https://finnhub.io/api/news?id=c3d898655d675adf9861075c19aae29112c5165f1503394a032fed2fd8ada182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754054082,
      "headline": "Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)",
      "id": 136167413,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after earnings. Read the latest stock analysis here.",
      "url": "https://finnhub.io/api/news?id=c3d898655d675adf9861075c19aae29112c5165f1503394a032fed2fd8ada182"
    }
  },
  {
    "ts": null,
    "headline": "Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?",
    "summary": "Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...",
    "url": "https://finnhub.io/api/news?id=b45faf4199a15e94dfb8b92ac7c8092615ed6a3e1eb0bdd2d2305abe88ac0d27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754049631,
      "headline": "Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?",
      "id": 136165560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...",
      "url": "https://finnhub.io/api/news?id=b45faf4199a15e94dfb8b92ac7c8092615ed6a3e1eb0bdd2d2305abe88ac0d27"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
    "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
    "url": "https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754046600,
      "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
      "id": 136166550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
      "url": "https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its Growth Portfolio and continued to optimize its cost structure. In the back half, Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing transformational medicines […]",
    "url": "https://finnhub.io/api/news?id=6c9d0fe75a2d34951cd21e52812ef785755a501fa2a54452659adad4cd2815fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754019168,
      "headline": "Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025",
      "id": 136161217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its Growth Portfolio and continued to optimize its cost structure. In the back half, Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing transformational medicines […]",
      "url": "https://finnhub.io/api/news?id=6c9d0fe75a2d34951cd21e52812ef785755a501fa2a54452659adad4cd2815fb"
    }
  }
]